Clinical Trial Update: XELOX Plus Apatinib vs XELOX as Post-operative Chemotherapy in Locally Advanced Gastric Signet Ring Carcinoma [Phase 3]

View source ↗

Summary

Phase 3 trial comparing XELOX plus Apatinib against XELOX alone as postoperative chemotherapy for locally advanced gastric signet-ring cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastric Signet-ring Cell Carcinoma

Drugs mentioned

• Apatinib (apatinib)
• Eloxatin (oxaliplatin)
• Xeloda (capecitabine)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Gastric Carcinoma | Phase 3 | Status: UNKNOWN